title: The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis. A cost-effectiveness analysis.
abstract: BACKGROUND
  After outbreaks of multidrug-resistant tuberculosis, the Centers for Disease Control and Prevention proposed the use of respirators with high-efficiency particulate air filters (HEPA respirators) as part of isolation precautions against tuberculosis, along with a respiratory-protection program for health care workers that includes medical evaluation, training, and tests of the fit of the respirators. Each HEPA respirator costs between $7.51 and $9.08, about 10 times the cost of respirators currently used.
  
  
  METHODS
  We conducted a cost-effectiveness analysis using data from the University of Virginia Hospital on exposure to patients with tuberculosis and rates at which the purified-protein-derivative (PPD) skin test became positive in hospital workers. The costs of a respiratory-protection program were based on those of an existing program for workers dealing with hazardous substances.
  
  
  RESULTS
  During 1992, 11 patients with documented tuberculosis were admitted to our hospital. Eight of 3852 workers (0.2 percent) had PPD tests that became positive. Five of these conversions were believed to be due to the booster phenomenon; one followed unprotected exposure to a patient not yet in isolation; the other two occurred in workers who had never entered a tuberculosis isolation room. These data suggest that it will take more than one year for the use of HEPA respirators to prevent a single conversion of the PPD test. Assuming that one conversion is prevented per year, however, it would take 41 years at out hospital to prevent one case of occupationally acquired tuberculosis, at a cost of $1.3 million to $18.5 million.
  
  
  CONCLUSIONS
  Given the effectiveness of currently recommended measures to prevent nosocomial transmission of tuberculosis, the addition of HEPA respirators would offer negligible protective efficacy at great cost.
authors.affiliation: University of Virginia Health Sciences Center, Charlottesville 22908.
authors.forename: K A
authors.initials: KA
authors.lastname: Adal
authors.forename: A M
authors.initials: AM
authors.lastname: Anglim
authors.forename: C L
authors.initials: CL
authors.lastname: Palumbo
authors.forename: M G
authors.initials: MG
authors.lastname: Titus
authors.forename: B J
authors.initials: BJ
authors.lastname: Coyner
authors.forename: B M
authors.initials: BM
authors.lastname: Farr
mesh_terms: D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000191:economics / Q000517:prevention & control*; D006801:Humans; D009784:Occupational Diseases / Q000191:economics / Q000517:prevention & control*; D014376:Tuberculosis / Q000191:economics / Q000517:prevention & control*; D012122:Ventilators, Mechanical / Q000191:economics*